Patient Square Capital

Patient Square Capital operates as a dedicated health care investment firm, founded in 2020 by James "Jim" Levin, a former executive from KKR. Levin's extensive background in the health care sector, including his 24-year tenure at KKR where he led the Health Care industry team for over a decade, provided the foundation for establishing a firm with a specialized focus. The firm launched with a substantial capital base, securing $3.9 billion for its inaugural fund, which notably exceeded its initial target.

The firm's core business is to make strategic investments across various domains of the health care industry. It targets companies whose products, services, or technologies have the potential to improve patient outcomes and overall community health. Patient Square Capital employs a partnership-driven approach, working closely with the management teams of its portfolio companies to foster growth and long-term value. This strategy leverages the firm's deep industry knowledge and extensive network of relationships.

Patient Square Capital's investment strategy encompasses a wide range of health care sub-sectors, including biopharmaceuticals, medical devices, diagnostics, and life science tools. The firm engages in various types of transactions, from growth equity investments in established companies to providing the capital for significant acquisitions. A notable transaction was the take-private acquisition of Syneos Health, a leading fully integrated biopharmaceutical solutions organization, in a deal valued at approximately $7.1 billion, which Patient Square led alongside Elliott Investment Management and Veritas Capital. This move illustrates the firm's capacity to execute large-scale, complex investments aimed at enhancing the capabilities of major players in the health services market. With approximately $8 billion in assets under management as of late 2023, the firm has established itself as a significant force in health care investing.

Keywords: health care investment, private equity, biopharmaceutical solutions, medical devices, life sciences, growth equity, strategic partnerships, patient outcomes, diagnostics, investment firm